Hemab raised $55M Series A led by Novo Holdings, HealthCap and RA Capital Management.

Hemab, a Copenhagen, Denmark-based biotech company developing next generation therapeutics for serious underserved bleeding and thrombosis disorders, announced the closing of a $55M Series A financing.

The money was raised from investors led by Novo Holdings, HealthCap and RA Capital Management.

As a result of the financing, Mårten Steen, Partner at HealthCap and Laura Tadvalkar, Principal at RA Capital Management, will join Jørgen Søberg Petersen, Partner at Novo Holdings and Hemab’s Chairman, Camilla Petrycer Hansen, Principal at Novo Seeds, and Thomas Batchelor on the Board of Directors.

Proceeds from the financing will be used to progress the Company’s promising pipeline of monoclonal and bispecific antibody-based therapeutics into later stages of development. The pipeline will initially focus on underserved people living with rare bleeding disorders such as Glanzmann’s Thrombasthenia (GT), with plans to expand into more common disorders of hemostasis and thrombosis. The financing will also enable Hemab to further build the team and expand its operational footprint in Denmark and the US.

Hemab, founded in 2020 by Johan Henrik Faber, Søren Bjørn, Hans Wandall, Thomas Batchelor and Mads Behrndt, aims to progress its pipeline of monoclonal and bispecific antibody-based therapeutics with the vision to transform the treatment paradigm for blood disease patients - from orphan disorders to broad indications with high unmet need.